Abstract 16587: Sodium Glucose Cotransporter-2 Inhibitors Post Acute Coronary Syndrome Induced New Heart Failure

Mace
DOI: 10.1161/circ.148.suppl_1.16587 Publication Date: 2023-12-19T08:08:02Z
ABSTRACT
Introduction: Patients with acute coronary syndrome (ACS) have an unmet need for further risk reduction in major adverse cardiovascular events (MACE) and heart failure (HF) development despite guideline-directed medical therapy. As sodium glucose cotransporter-2 inhibitors (SGLT2i) are cardioprotective, this study, we assessed the effectiveness of SGLT2i post-ACS new onset HF. Hypothesis: use improves outcomes induced Methods: We conducted a retrospective observational cohort study that included all diabetic patients admitted to main tertiary cardiology center Qatar between 1/06/2017 1/06/2021 ACS complicated by HF defined as clinical requiring diuretics during index admission, or ejection fraction (EF) <40%. divided population two groups; (1) users; (2) non-SGLT2i users. Primary were evaluated at 30 360 days, including composite ACS, hospitalization, all-cause mortality. A propensity score-matched model (1:1) was used adjust baseline characteristics groups. Cox proportional hazard regression analysis evaluate outcomes. P-value <0.05 indicated statistical significance. Results: 465 who met eligibility criteria (93% male, mean age 55±10 years, 72% Asian). Using 1:1 score matching, 78 per arm absolute standardized difference <0.1 characteristics. The post ischemia-induced resulted lower days [ 30-day: 2.6% vs. 11.5%, HR= 0.20 (0.04-0.94), P =0.041; 360-Day: 14.1% 23.1, 0.46 (0.22-0.99), P= 0.046]. Conclusions: Our findings suggest cardioprotective effects HF, which widens spectrum indications may encourage cardiologists prescribe population.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)